Thus, altered Tfh/Tfr imbalance may be a potential therapeutic target for IBD, while Tnfaip6 might also be expected to become an alternative treatment option for MSC transplantation in IBD in the future. This evidence concerns the gene TNFAIP6 and inflammatory bowel disease.